Exciting results - strengthening the ANP patents on combo therapy with Exon skipping drugs...and the necessary nerdy data to get Sarepta's attention.
Given our PI for the P2B trial is Dr Voit - who is one of the inventors of Micro-dystrophin IP used by Sarepta, maybe the lines of communication are finally open?
No dystrophin, just increase in muscle and reduced inflammation - with a 33% increase in the MyoM1 protein...and modulation of BTLA and FABP4.
Just need the money tox study to drop end of year, and the US door opens a little more.
.
Exciting results - strengthening the ANP patents on combo...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.7¢ | 7.9¢ | 7.6¢ | $148.9K | 1.895M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 48919 | 7.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.9¢ | 70000 | 1 |
View Market Depth
| Last trade - 15.59pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.8¢ |
Change
0.000 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 7.7¢ | 7.9¢ | 7.7¢ | 43057 | ||
| Last updated 13.04pm 03/05/2024 ? | |||||
| PER (ASX) Chart |